Zai Lab Limited ADR (NASDAQ:ZLAB) has a beta value of 1.08 and has seen 1.22 million shares traded in the last trading session. The company, currently valued at $3.57B, closed the last trade at $32.53 per share which meant it gained $2.82 on the day or 9.49% during that session. The ZLAB stock price is -22.26% off its 52-week high price of $39.77 and 55.49% above the 52-week low of $14.48. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.96 million shares traded. The 3-month trading volume is 1.18 million shares.
The consensus among analysts is that Zai Lab Limited ADR (ZLAB) is Buy stock at the moment, with a recommendation rating of 1.29. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.55.
Zai Lab Limited ADR (NASDAQ:ZLAB) trade information
Sporting 9.49% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ZLAB stock price touched $32.53 or saw a rise of 0.52%. Year-to-date, Zai Lab Limited ADR shares have moved 24.21%, while the 5-day performance has seen it change 3.20%. Over the past 30 days, the shares of Zai Lab Limited ADR (NASDAQ:ZLAB) have changed -7.30%. Short interest in the company has seen 7.32 million shares shorted with days to cover at 7.5.
Wall Street analysts have a consensus price target for the stock at $55, which means that the shares’ value could jump 40.85% from current levels. The projected low price target is $55.0 while the price target rests at a high of $55.0. In that case, then, we find that the current price level is -69.07% off the targeted high while a plunge would see the stock gain -69.07% from current levels.
Zai Lab Limited ADR (ZLAB) estimates and forecasts
The company’s shares have gained 23.41% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 41.92%.
5 analysts offering their estimates for the company have set an average revenue estimate of 116.54M for the current quarter. 5 have an estimated revenue figure of 129.27M for the next ending quarter. Year-ago sales stood 87.15M and 100.5M respectively for this quarter and the next, and analysts expect sales will grow by 33.72% for the current quarter and 41.92% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -3.18% over the past 5 years.
ZLAB Dividends
Zai Lab Limited ADR is expected to release its next earnings report on 2025-Feb-26 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Zai Lab Limited ADR (NASDAQ:ZLAB)’s Major holders
Insiders own 1.44% of the company shares, while shares held by institutions stand at 54.55% with a share float percentage of 55.34%. Investors are also buoyed by the number of investors in a company, with Zai Lab Limited ADR having a total of 188.0 institutions that hold shares in the company. The top two institutional holders are WELLINGTON MANAGEMENT GROUP LLP with over 7.12 million shares worth more than $123.47 million. As of 2024-06-30, WELLINGTON MANAGEMENT GROUP LLP held 0.73% of shares outstanding.
The other major institutional holder is JANUS HENDERSON GROUP PLC, with the holding of over 6.53 million shares as of 2024-06-30. The firm’s total holdings are worth over $113.13 million and represent 0.6689% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are New World Fund Inc and VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund . As of Mar 31, 2025 , the former fund manager holds about 2.97% shares in the company for having 3.27 shares of worth $106.51 million while later fund manager owns 2.9 shares of worth $94.2 million as of Jan 31, 2025 , which makes it owner of about 2.63% of company’s outstanding stock.
